Page last updated: 2024-11-07
dichlororibofuranosylbenzimidazole and Experimental Leukemia
dichlororibofuranosylbenzimidazole has been researched along with Experimental Leukemia in 2 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Tweeten, KA | 1 |
Molloy, GR | 2 |
Mukherjee, R | 1 |
Other Studies
2 other studies available for dichlororibofuranosylbenzimidazole and Experimental Leukemia
Article | Year |
---|---|
Induction of premature termination of transcription of the mouse beta-globin gene by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB).
Topics: Animals; Cell Line; Clone Cells; Cloning, Molecular; Dichlororibofuranosylbenzimidazole; DNA Restric | 1981 |
5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription of the beta-hemoglobin gene in vivo at initiation.
Topics: Animals; Cell Line; Cell Nucleus; Dichlororibofuranosylbenzimidazole; Genes; Hemoglobins; Kinetics; | 1987 |